Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07516561) titled 'Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia' on April 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Apsen Farmaceutica S.A.
Condition:
Alopecia, Androgenetic
Intervention:
Drug: APSMNF 1
Drug: APSMNF 2
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: July 7, 2026
Target Sample Size: 336
Countries of Recruitment:
Brazil
To know more, visit https://clinicaltrials.gov/study/NCT07516561
Publish...